While there are promising preliminary results among breast cancer and NSCLC patients treated with the IGF1R inhibitor Dalotuzumab,[74] according to our results, the subgroup of male patients with NSCLC appears to benefit the most of such a treatment. The gene discussed is IGF1R; the disease is breast cancer.